

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

CLOSURE OF REGISTER OF MEMBERS OF H SHARES FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

Reference is made to the announcement (the “**Announcement**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) dated August 26, 2026 in relation to, among other things, the proposed appointment of Ms. Fei as an independent non-executive director of the Company (the “**Proposed Appointment**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board hereby announces that the 2026 first extraordinary general meeting of the Company (the “**EGM**”) will be held on Friday, October 9, 2026 at Room 302, 3/F, Building 4, No. 590 Ruiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC for the purpose of considering and, if thought fit, approving the Proposed Appointment.

For the purpose of determining the entitlement of holders of H shares to attend and vote at the EGM, the register of members of H shares of the Company (“**H Shares**”) will be closed from Saturday, September 19, 2026 to Friday, October 9, 2026, both days inclusive. Shareholders holding H Shares whose names appear on the register of members of H Shares on Friday, October 9, 2026 will be entitled to attend and vote at the EGM. During such period, no transfer of H Shares will be registered.

In order to be eligible to attend and to vote at the EGM, all properly completed transfer documents, accompanied by relevant share certificates, must be lodged with the Company's H shares registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Friday, September 18, 2026 for registration.

A circular containing, among other things, details of the Proposed Appointment, together with a notice of the EGM, will be dispatched to the shareholders of the Company as soon as practicable.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, September 4, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive Directors.